Search

Your search keyword '"Nishihara, Kiyoaki"' showing total 140 results
Start Over Author "Nishihara, Kiyoaki"
140 results on '"Nishihara, Kiyoaki"'

1. Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study

Author

Kato, Minoru, Taoka, Rikiya, Miki, Jun, Saito, Ryoichi, Fukuokaya, Wataru, Matsui, Yoshiyuki, Yamamoto, Shoma, Matsue, Taisuke, Hatakeyama, Shingo, Kawahara, Takashi, Matsuda, Ayumu, Kawai, Taketo, Sazuka, Tomokazu, Sano, Takeshi, Urabe, Fumihiko, Kashima, Soki, Naito, Hirohito, Murakami, Yoji, Miyake, Makito, Daizumoto, Kei, Matsushita, Yuto, Hayashi, Takuji, Inokuchi, Junichi, Sugino, Yusuke, Shiga, Kenichiro, Yamaguchi, Noriya, Yamamoto, Shingo, Yasue, Keiji, Abe, Takashige, Nakanishi, Shotaro, Hashine, Katsuyoshi, Fujii, Masato, Nishihara, Kiyoaki, Matsumoto, Hiroaki, Tatarano, Shuichi, Wada, Koichiro, Sekito, Sho, Maruyama, Ryo, Nishiyama, Naotaka, Nishiyama, Hiroyuki, Kitamura, Hiroshi, and Uchida, Junji

Published
2024
Full Text
View/download PDF

2. Effects of long‐term desmopressin treatment for nocturia in older people.

Author

Kurose, Hirofumi, Ueda, Kosuke, Chikui, Katsuaki, Uemura, Keiichiro, Nishihara, Kiyoaki, Nakiri, Makoto, Suekane, Shigetaka, and Igawa, Tsukasa

Subjects
NOCTURIA, TREATMENT effectiveness, DESMOPRESSIN, PEPTIDES, BODY composition
Abstract

Objectives: Desmopressin improves nocturia frequency; however, reports on its long‐term efficacy and safety are few, and concerns regarding its effect on body composition exist. We thus investigated the efficacy and safety of long‐term desmopressin administration and its effect on body composition. Methods: This retrospective study, conducted at Chikugo City Hospital between August 2020 and December 2022, involved 133 men (mean age, 77.7 years) with nocturnal and persistent nocturia, who were administered an initial dose of 50 μg desmopressin. Efficacy endpoints included nocturnal urinary frequency, nocturnal urinary volume, hours of undisturbed sleep, nocturnal polyuria index, initial nocturnal urinary volume, and daily urinary frequency in a frequency‐volume chart (3 days), before treatment and at 1, 4, 12, 24, and 52 weeks after desmopressin administration. Additionally, the effects of desmopressin on body composition were examined, including blood–brain natriuretic peptide and a chest radiography, before and 52 weeks after administration. Results: Treatment improved most efficacy endpoint evaluation parameters. Around 87.6% of patients showed improved symptoms after 52 weeks compared with those before treatment (score ≤ 3). The blood–brain natriuretic peptide level rose; however, cardiothoracic ratio was unchanged. Conclusion: Long‐term administration of desmopressin is thus effective and safe in older people with nocturnal polyuria, with little effect on body composition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan

Author

Kikuchi, Eiji, primary, Hayakawa, Nozomi, additional, Nakayama, Masashi, additional, Uno, Masahiro, additional, Nakatsu, Hiroomi, additional, Kitagawa, Chiyoe, additional, Miyake, Hideaki, additional, Yamada, Takeshi, additional, Fujita, Kazutoshi, additional, Shimoyama, Hideaki, additional, Nishihara, Kiyoaki, additional, Kobayashi, Mizuki, additional, Nakamura, Motonobu, additional, Fujimoto, Kiyohide, additional, Sano, Takeshi, additional, Nishiyama, Naotaka, additional, Ito, Takayuki, additional, Kajita, Masahiro, additional, Kobayashi, Takashi, additional, and Kitamura, Hiroshi, additional

Published
2024
Full Text
View/download PDF

6. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.

Author

Ueda, Kosuke, Uemura, Keiichiro, Ito, Naoki, Sakai, Yuya, Ohnishi, Satoshi, Suekane, Hiroki, Kurose, Hirofumi, Hiroshige, Tasuku, Chikui, Katsuaki, Nishihara, Kiyoaki, Nakiri, Makoto, Suekane, Shigetaka, Ogasawara, Sachiko, Yano, Hirohisa, and Igawa, Tsukasa

Subjects
IMMUNE checkpoint proteins, RENAL cell carcinoma, PROTEIN expression, APOPTOSIS, MULTIVARIATE analysis, RECEPTOR for advanced glycation end products (RAGE)
Abstract

Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC. The expression of soluble programmed cell death-1 (sPD-1), soluble programmed cell death ligand-1 (sPD-L1), soluble PD-L2 (sPD-L2), and lymphocyte activation gene-3 (sLAG-3) was assessed in plasma samples from 42 patients with advanced RCC who received first-line IO combination therapy. All IMDC risk classifications were represented among the patients, including 14.3, 57.1, and 28.6% with favorable, intermediate, and poor risk, respectively. Univariate analysis revealed that prior nephrectomy, sPD-L2 levels, and sLAG-3 levels were significant factors affecting progression-free survival (PFS), whereas multivariate analyses suggested that sPD-L2 and sLAG-3 levels were independent prognostic factors for PFS. In a univariate analysis of the overall survival, prior nephrectomy and sPD-L2 levels were significant factors; no significant differences were observed in the multivariate analysis. No significant correlation was observed between the sPD-L2 and sLAG-3 levels and PD-L2 and LAG-3 expression via immunohistochemistry. In conclusion, sPD-L2 and sLAG-3 expression may serve as a potential biomarker for predicting IO combination therapy efficacy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Sarcopenia and the Therapeutic Effects of Androgen Receptor-axis-targeted Therapies in Patients With Castration-resistant Prostate Cancer

Author

HIROSHIGE, TASUKU, OGASAWARA, NAOYUKI, KUMAGAE, HISAJI, UEDA, KOSUKE, CHIKUI, KATSUAKI, UEMURA, KEI-ICHIRO, NISHIHARA, KIYOAKI, NAKIRI, MAKOTO, MATSUO, MITSUNORI, SUEKANE, SHIGETAKA, and IGAWA, TSUKASA

Subjects
Pharmacology, Cancer Research, General Biochemistry, Genetics and Molecular Biology, Research Article
Abstract

Background/Aim: Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass and has been reported to be a poor prognostic factor for taxane-treated castration-resistant prostate cancer (CRPC). However, whether sarcopenia affects androgen receptor axis-targeted therapies (ARATs) remains unknown. In the present study, we investigated the association between sarcopenia in CRPC and treatment outcomes of ARATs. Patients and Methods: From January 2015 to September 2022, 127 patients who received ARATs as 1(st)-line treatment for CRPC at our two hospitals were included in the study. We retrospectively evaluated sarcopenia using computed tomography images and investigated whether sarcopenia affects the progression-free survival (PFS) and overall survival (OS) of patients with CRPC treated with ARATs. Results: Out of 127 patients, 99 were diagnosed with sarcopenia. The PFS of the sarcopenic group administered ARATs was significantly better than that of the non-sarcopenic group. Furthermore, in the multivariate analysis of PFS, sarcopenia was an independent favourable prognostic factor. However, there was no significant difference in the OS between the sarcopenic and non-sarcopenia groups. Conclusion: ARATs could more effectively treat patients with CRPC and sarcopenia than patients with CRPC without sarcopenia. Sarcopenia may positively influence the therapeutic effects of ARATs.

Published
2023
Full Text
View/download PDF

8. Investigation of Effect Predictors of Desmopressin in Nocturia Patients With Nocturnal Polyuria.

Author

KUROSE, HIROFUMI, OGASAWARA, NAOYUKI, UEDA, KOSUKE, CHIKUI, KATSUAKI, UEMURA, KEIICHIRO, NISHIHARA, KIYOAKI, NAKIRI, MAKOTO, SUEKANE, SHIGETAKA, and IGAWA, TSUKASA

Subjects
DESMOPRESSIN, NOCTURIA, POLYURIA, QUALITY of life, INSOMNIA
Abstract

Background/Aim: Effect predictors of desmopressin for nocturia associated with nocturnal polyuria are understudied. Herein, we investigated the effects of desmopressin on sleep and patient quality of life. We defined cases in which administration of desmopressin led to hours of undisturbed sleep (HUS) ≥3 hours as "marked response cases" and examined predictive factors of desmopressin treatment response. Patients and Methods: Our study included 129 patients who were administered desmopressin 50 μg for nocturia associated with nocturnal polyuria at our hospital. Efficacy and safety of desmopressin were examined using bladder diaries, International Prostate Symptom Score, Overactive Bladder Symptom Score, Athens Insomnia Scale, Patient Global Impression of Improvement (PGI-I) score, physical examinations, blood tests, and body composition analyzers, and the predictors of desmopressin efficacy were investigated. Results: Significant improvements in all endpoints were observed from the early stage onward after desmopressin treatment compared with before treatment. After treatment, HUS was significantly longer in patients with good PGI-I scores, which indicated patient satisfaction. Variation in nocturnal micturition frequency did not affect the improvement in patient satisfaction. Examination of cases defined as "marked response cases" showed that the mean night-time urine volume was an independent predictor of treatment response. Conclusion: Desmopressin can improve patients' quality of life and sleep by extending HUS. This suggests that desmopressin may be effective in patients with high mean night-time urine volumes based on their bladder diary. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Author

Ueda, Kosuke, primary, Ogasawara, Naoyuki, additional, Ito, Naoki, additional, Ohnishi, Satoshi, additional, Suekane, Hiroki, additional, Kurose, Hirofumi, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Uemura, Keiichiro, additional, Nishihara, Kiyoaki, additional, Nakiri, Makoto, additional, Suekane, Shigetaka, additional, and Igawa, Tsukasa, additional

Published
2023
Full Text
View/download PDF

13. Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I‐125 low‐dose‐rate brachytherapy for localized prostate cancer

Author

Ogasawara, Naoyuki, primary, Nakiri, Makoto, additional, Kurose, Hirofumi, additional, Ueda, Kosuke, additional, Chikui, Katsuaki, additional, Nishihara, Kiyoaki, additional, Matsuo, Mitsunori, additional, Suekane, Shigetaka, additional, Morimatsu, Yoshitaka, additional, Murotani, Kenta, additional, Muraki, Koichiro, additional, Hattori, Chikayuki, additional, Ogo, Etsuyo, additional, Ishitake, Tatsuya, additional, and Igawa, Tsukasa, additional

Published
2022
Full Text
View/download PDF

15. Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan

Author

Fujimoto, Naohiro, Kubo, Tatsuhiko, Hisaoka, Masanori, Udo, Kazuma, Yokomizo, Akira, Shibuya, Tadamasa, Wakeda, Hironobu, Nishihara, Kiyoaki, Moriya, Ryosuke, Iwakuma, Keiko, Eto, Masatoshi, Naito, Seiji, Furuya, Ryusaburo, Tanaka, Masatoshi, Ishii, Tatsu, Igawa, Tsukasa, Noguchi, Mitsuru, Takehara, Kosuke, Hakariya, Tomoaki, Sakai, Hideki, Mimata, Hiromitsu, Kawano, Yoshiaki, Kamba, Tomomi, Kamoto, Toshiyuki, Yamane, Takashi, Nakagawa, Masayuki, Oshiro, Yoshinori, Ashimine, Satoshi, and Saito, Seiichi

Published
2018
Full Text
View/download PDF

17. Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy

Author

UEDA, KOSUKE, primary, SUEKANE, SHIGETAKA, additional, KUROSE, HIROFUMI, additional, ITO, NAOKI, additional, OGASAWARA, NAOYUKI, additional, HIROSHIGE, TASUKU, additional, CHIKUI, KATSUAKI, additional, EJIMA, KAZUHISA, additional, UEMURA, KEIICHIRO, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, and IGAWA, TSUKASA, additional

Published
2022
Full Text
View/download PDF

18. Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I‐125 low‐dose‐rate brachytherapy for localized prostate cancer.

Author

Ogasawara, Naoyuki, Nakiri, Makoto, Kurose, Hirofumi, Ueda, Kosuke, Chikui, Katsuaki, Nishihara, Kiyoaki, Matsuo, Mitsunori, Suekane, Shigetaka, Morimatsu, Yoshitaka, Murotani, Kenta, Muraki, Koichiro, Hattori, Chikayuki, Ogo, Etsuyo, Ishitake, Tatsuya, and Igawa, Tsukasa

Subjects
SARCOPENIA, PROSTATE cancer, RADIOISOTOPE brachytherapy, FAT, LOGISTIC regression analysis
Abstract

Objectives: To evaluate the effects of sarcopenia and excess visceral fat accumulation on early urinary function after I‐125 low‐dose‐rate brachytherapy for prostate cancer. Methods: We retrospectively reviewed consecutive patients who underwent brachytherapy for prostate cancer. Pre‐treatment computed tomography was used to measure skeletal muscle index at the L3 level to assess sarcopenia and visceral fat area at the umbilical level. The International Prostate Symptom Score and the University of California Los Angeles Prostate Cancer Index were used to assess quality of life during the 24 months after brachytherapy. Logistic regression analysis was used to examine whether sarcopenia and excess visceral fat accumulation had clinically significant effects on post‐treatment quality of life. Results: Among 246 patients, 92 (37.4%) were stratified into the sarcopenia group and 141 (57.3%) into the excess visceral fat accumulation group. The sarcopenia group had significantly lower University of California Los Angeles Prostate Cancer Index urinary function than the non‐sarcopenia group 24 months post‐brachytherapy. The excess visceral fat accumulation group had significantly poorer International Prostate Symptom Score total, storage, and voiding scores than the non‐excess accumulation group 12 months post‐brachytherapy. In the multivariate analysis, sarcopenia had a clinically significant adverse effect on the University of California Los Angeles Prostate Cancer Index urinary function at 12 months. Excess visceral fat accumulation had a clinically significant adverse effect on the International Prostate Symptom Score voiding and storage scores at 12 months. Conclusions: Sarcopenia and excess visceral fat accumulation negatively affect urinary function early after I‐125 low‐dose‐rate brachytherapy for prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis

Author

Mukai, Shoichiro, primary, Sakamoto, Naotaka, additional, Kakinoki, Hiroaki, additional, Shibuya, Tadamasa, additional, Moriya, Ryosuke, additional, Nishihara, Kiyoaki, additional, Noguchi, Mitsuru, additional, Shin, Toshitaka, additional, Fujimoto, Naohiro, additional, Igawa, Tsukasa, additional, Ishii, Tatsu, additional, Haga, Nobuhiro, additional, Enokida, Hideki, additional, Eto, Masatoshi, additional, Kamba, Tomomi, additional, Sakai, Hideki, additional, Saito, Seiichi, additional, Terada, Naoki, additional, and Kamoto, Toshiyuki, additional

Published
2022
Full Text
View/download PDF

20. Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate

Author

Nakiri, Makoto, primary, Ueda, Kosuke, additional, Ogasawara, Naoyuki, additional, Kurose, Hirofumi, additional, Uemura, Keiichiro, additional, Nishihara, Kiyoaki, additional, Muraki, Koichiro, additional, Hattori, Chikayuki, additional, Ogo, Etsuyo, additional, and Igawa, Tsukasa, additional

Published
2022
Full Text
View/download PDF

23. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab

Author

Ueda, Kosuke, primary, Suekane, Shigetaka, additional, Kurose, Hirofumi, additional, Ito, Naoki, additional, Ogasawara, Naoyuki, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Ejima, Kazuhisa, additional, Uemura, Keiichiro, additional, Nakiri, Makoto, additional, Nishihara, Kiyoaki, additional, and Igawa, Tsukasa, additional

Published
2022
Full Text
View/download PDF

24. Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan

Author

Nakiri, Makoto, primary, Ogasawara, Naoyuki, additional, Kurose, Hirofumi, additional, Ueda, Kosuke, additional, Chikui, Katsuaki, additional, Nishihara, Kiyoaki, additional, Ejima, Kazuhisa, additional, Uemura, Keiichiro, additional, Murotani, Kenta, additional, Muraki, Koichiro, additional, Hattori, Chikayuki, additional, Ogo, Etsuyo, additional, Morimatsu, Yoshitaka, additional, Ishitake, Tatsuya, additional, and Igawa, Tsukasa, additional

Published
2022
Full Text
View/download PDF

26. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab

Author

Ueda, Kosuke, primary, Suekane, Shigetaka, additional, Kurose, Hirofumi, additional, Ogasawara, Naoyuki, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Uemura, Keiichiro, additional, Nakiri, Makoto, additional, Nishihara, Kiyoaki, additional, Matsuo, Mitsunori, additional, and Igawa, Tsukasa, additional

Published
2021
Full Text
View/download PDF

27. Surveillance of urachal abscess in the Kyushu–Okinawa area of Japan

Author

Tobu, Shohei, primary, Udo, Kazuma, additional, Nishihara, Kiyoaki, additional, Miyajima, Shigero, additional, Ando, Tadasuke, additional, Onizuka, Chie, additional, Itesako, Toshihiko, additional, Ashikari, Asuka, additional, Hakariya, Tomoaki, additional, Igawa, Tsukasa, additional, Tanaka, Masatoshi, additional, Shin, Toshitaka, additional, Kamoto, Toshiyuki, additional, Nakagawa, Masayuki, additional, Saito, Seiichi, additional, Sakai, Hideki, additional, Eto, Masatoshi, additional, Kamba, Tomomi, additional, Fujimoto, Naohiro, additional, and Noguchi, Mitsuru, additional

Published
2021
Full Text
View/download PDF

30. Longitudinal Changes in Health-related Quality of Life After 125I Low-dose-rate Brachytherapy for Localized Prostate Cancer

Author

OGASAWARA, NAOYUKI, primary, NAKIRI, MAKOTO, additional, KUROSE, HIROFUMI, additional, UEDA, KOSUKE, additional, CHIKUI, KATSUAKI, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, SUEKANE, SHIGETAKA, additional, MUROTANI, KENTA, additional, MURAKI, KOICHIRO, additional, HATTORI, CHIKAYUKI, additional, OGO, ETSUYO, additional, IGAWA, TUKASA, additional, and ISHITAKE, TATSUYA, additional

Published
2020
Full Text
View/download PDF

31. Paraganglioma of the urinary bladder: Case report and literature review

Author

Kurose, Hirofumi, primary, Ueda, Kosuke, additional, Uegaki, Mami, additional, Ogasawara, Naoyuki, additional, Kumagae, Hisaji, additional, Chikui, Katsuaki, additional, Nakiri, Makoto, additional, Nishihara, Kiyoaki, additional, Matsuo, Mitsunori, additional, Suekane, Shigetaka, additional, Akiba, Jun, additional, Yano, Hirohisa, additional, and Igawa, Tsukasa, additional

Published
2020
Full Text
View/download PDF

32. The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies

Author

UEDA, KOSUKE, primary, OGASAWARA, NAOYUKI, additional, YONEKURA, SATORU, additional, MATSUNAGA, YOSHIHIRO, additional, HOSHINO, RYUJI, additional, KUROSE, HIROFUMI, additional, CHIKUI, KATSUAKI, additional, UEMURA, KEIICHIRO, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, SUEKANE, SHIGETAKA, additional, and IGAWA, TSUKASA, additional

Published
2020
Full Text
View/download PDF

34. Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer

Author

KUROSE, HIROFUMI, primary, UEDA, KOSUKE, additional, KONDO, REIICHIRO, additional, OGASAWARA, SACHIKO, additional, KUSANO, HIRONORI, additional, SANADA, SAKIKO, additional, NAITO, YOSHIKI, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, KAKUMA, TATSUYUKI, additional, AKIBA, JUN, additional, IGAWA, TSUKASA, additional, and YANO, HIROHISA, additional

Published
2019
Full Text
View/download PDF

35. The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors

Author

UEDA, KOSUKE, primary, YONEKURA, SATORU, additional, OGASAWARA, NAOYUKI, additional, MATSUNAGA, YOSHIHIRO, additional, HOSHINO, RYUJI, additional, KUROSE, HIROFUMI, additional, CHIKUI, KATSUAKI, additional, UEMURA, KEIICHIRO, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, SUEKANE, SHIGETAKA, additional, and IGAWA, TSUKASA, additional

Published
2019
Full Text
View/download PDF

40. Abstract 1546: Low-molecular-weight protein tyrosine phosphatase is a useful biomarker for predicting postoperative biochemical recurrence in RM0 prostate cancer

Author

Kurose, Hirofumi, primary, Ueda, Kosuke, additional, Kondo, Reiichiro, additional, Nishihara, Kiyoaki, additional, Nakiri, Makoto, additional, Matsuo, Mitsunori, additional, Suekane, Shigetaka, additional, Sanada, Sakiko, additional, Ogasawara, Sachiko, additional, Igawa, Tsukasa, additional, and Yano, Hirohisa, additional

Published
2018
Full Text
View/download PDF

42. Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies

Author

Ueda, Kosuke, primary, Suekane, Shigetaka, additional, Nishihara, Kiyoaki, additional, Suekane, Hiroki, additional, Ogasawara, Naoyuki, additional, Kurose, Hirofumi, additional, Chikui, Katsuaki, additional, Ejima, Kazuhisa, additional, Suyama, Shunsuke, additional, Nakiri, Makoto, additional, Matsuo, Mitsunori, additional, and Igawa, Tsukasa, additional

Published
2017
Full Text
View/download PDF

43. MP78-06 PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR METASTATIC UPPER TRACT UROTHELIAL CANCER PATIENTS REFRACTORY TO THE STANDARD CHEMOTHERAPY

Author

Suekane, Shigetaka, primary, Ueda, Kousuke, additional, Nishihara, Kiyoaki, additional, Igawa, Tsukasa, additional, Noguchi, Masanori, additional, Sasada, Tetsuro, additional, Yamashita, Takuto, additional, Yutani, Shigeru, additional, Shichijo, Shigeki, additional, and Itoh, Kyogo, additional

Published
2017
Full Text
View/download PDF

46. Spontaneous regression of multiple pulmonary nodules in a patient with unclassified renal cell carcinoma following laparoscopic partial nephrectomy: A case report

Author

UEDA, KOSUKE, primary, SUEKANE, SHIGETAKA, additional, MITANI, TOMOTARO, additional, CHIKUI, KATSUAKI, additional, EJIMA, KAZUHISA, additional, SUYAMA, SHUNSUKE, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, and IGAWA, TSUKASA, additional

Published
2016
Full Text
View/download PDF

50. Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.

Author

Kosuke Ueda, Shigetaka Suekane, Naoyuki Ogasawara, Katsuaki Chikui, Shunsuke Suyama, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Tsukasa Igawa, Ueda, Kosuke, Suekane, Shigetaka, Ogasawara, Naoyuki, Chikui, Katsuaki, Suyama, Shunsuke, Nakiri, Makoto, Nishihara, Kiyoaki, Matsuo, Mitsunori, and Igawa, Tsukasa

Subjects
DISEASE progression, METASTASIS, SORAFENIB, THERAPEUTICS
Abstract

Background: Molecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. However, patients in whom the treatment could initially be effective will experience disease progression later.Case Presentation: A 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction, occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe adverse events.Conclusions: We present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10 years while receiving sorafenib monotherapy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results